|
gptkbp:instanceOf
|
gptkb:biotechnology
|
|
gptkbp:acquiredBy
|
Viartis biosimilars business
|
|
gptkbp:CEO
|
gptkb:Shreehas_Tambe
|
|
gptkbp:country
|
gptkb:India
|
|
gptkbp:focus
|
immunology
oncology
biosimilars
diabetes care
monoclonal antibodies
insulins
|
|
gptkbp:foundedYear
|
2019
|
|
gptkbp:headquartersLocation
|
gptkb:Bengaluru
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Biocon Biologics
|
|
gptkbp:industry
|
gptkb:biotechnology
pharmaceuticals
|
|
gptkbp:listedOn
|
not separately listed (subsidiary of Biocon Limited)
|
|
gptkbp:market
|
gptkb:Africa
gptkb:Asia
gptkb:Europe
gptkb:India
gptkb:Latin_America
gptkb:United_States
|
|
gptkbp:numberOfEmployees
|
over 4000
|
|
gptkbp:parentCompany
|
gptkb:Biocon_Limited
|
|
gptkbp:partner
|
gptkb:Viartis
gptkb:Sandoz
gptkb:Mylan
gptkb:Serum_Institute_of_India
|
|
gptkbp:product
|
gptkb:Semglee
gptkb:Adalimumab
gptkb:Etanercept
gptkb:Fulphila
gptkb:Insulin_Glargine
gptkb:Ogivri
gptkb:Pegfilgrastim
gptkb:Trastuzumab
gptkb:Bevacizumab
|
|
gptkbp:regulatoryApprovals
|
gptkb:US_FDA
gptkb:EMA
gptkb:Health_Canada
gptkb:TGA
|
|
gptkbp:website
|
https://www.biocon.com/biocon-biologics/
|
|
gptkbp:bfsParent
|
gptkb:Biocon
gptkb:Biocon_Limited
|
|
gptkbp:bfsLayer
|
6
|